We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Protein Biomarker Predicts Cardiac Fibrosis Sequelae

By LabMedica International staff writers
Posted on 13 Sep 2012
Print article
The relationship between the level of galectin-3 (Gal-3) in the blood and the incidence of heart failure has been examined in a large population study.

Galectin-3 is emerging as an important prognostic protein biomarker as a mediator of cardiac fibrosis and measuring levels of Gal-3 in the blood may offer a way to identify high-risk individuals who could benefit from treatments to prevent debilitating heart failure and death.

Scientists at the US National Heart, Lung, and Blood Institute's Heart Study, (Framingham, MA, USA) measured Gal-3 levels in the blood of 3,353 participants in the Framingham Offspring Cohort. At the time of measurement, the average age of the participants was 59 years old, and 52% were female. Plasma concentrations of Gal-3 were measured using an enzyme-linked immunosorbent assay (ELISA). The lower detection limit was 1.32 ng/mL, with an upper detection limit of 96.6 ng/mL.

During an average follow-up of 11 years, 166 participants (5.1%) had a first heart failure event. Among the 25% of people with the highest galectin-3 levels, ranging from 15.4 ng/mL to 52.1 ng/mL, the annual rate of heart failure was 12/1,000 people compared with 3/1,000 people for the 25% of participants with the lowest Gal-3 levels which ranged from 3.9 ng/mL to 12 ng/mL. The ELISA used to measure Gal-3 levels was manufactured by BG Medicine (Waltham, MA, USA).

The authors concluded that their findings demonstrated that higher levels of Gal-3, a marker of cardiac fibrosis, are associated with an increased risk for incident heart failure and all-cause mortality in the community. Their study is the first to report the association of Gal-3 with risk for new-onset heart failure in apparently healthy subjects. The data also suggests that the association of Gal-3 with incident heart failure may be influenced by kidney function. The study was published on August 29, 2012, in the Journal of the American College of Cardiology.

Related Links:

US National Heart, Lung, and Blood Institute
BG Medicine


New
Gold Member
Chagas Disease Test
CHAGAS Cassette
Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
New
FAP Immunoassay
Quantikine QuicKit Human FAP ELISA
New
Urine Drug Test
Instant-view Propoxyphene Urine Drug Test

Print article

Channels

Molecular Diagnostics

view channel
Image: A coronal MRI section shows a high-intensity focused ultrasound lesion in the left thalamus of the brain (Photo courtesy of UT Southwestern Medical Center)

Newly Identified Stroke Biomarkers Pave Way for Blood Tests to Quickly Diagnose Brain Injuries

Each year, nearly 800,000 individuals in the U.S. experience a stroke, which occurs when blood flow to specific areas of the brain is insufficient, causing brain cells to die due to a lack of oxygen.... Read more

Immunology

view channel
Image: The discovery of biomarkers could improve endometrial cancer treatment (Photo courtesy of Mount Sinai)

Simple Blood Test Could Help Choose Better Treatments for Patients with Recurrent Endometrial Cancer

Endometrial cancer, which develops in the lining of the uterus, is the most prevalent gynecologic cancer in the United States, affecting over 66,000 women annually. Projections indicate that in 2025, around... Read more

Pathology

view channel
Image: As tumor cells flow through these microfluidic chambers, they are subjected to increasing shear stress and sorted based on their adhesion strength (Photo courtesy of UC San Diego)

Microfluidic Device Assesses Stickiness of Tumor Cells to Predict Cancer Spread

Ductal carcinoma in situ (DCIS), a type of early-stage breast cancer, is often referred to as stage zero breast cancer. In many cases, it remains harmless and does not spread beyond the milk ducts where... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.